Canacord Today
NXS-ASX | Dec quarterly; maintain BUY and A$3.04 target
NXS-ASX | Price A$2.33 | Market Cap A$419.2M
BUY Unchanged
PRICE TARGET A$3.04 Unchanged
Investment Recommendation
The Next Science (NXS) quarterly saw cash receipts fall in the quarter to $0.4m v $0.9m for the previous quarter, with sales of US$4.1m, US$0.7m lower than forecast. Cash on hand is US$16.9m.This IPO year has been subject to delay on the product approval front and disruption with its key wound care product BlastX resulting from the acquisition of KCI Acelity (KCI) by distribution partner 3M. That acquisition concluded in October, and there were retrenchments at 3M. However, BlastX is now part of the KCI sales budget and the run rate in January appears promising. Recent testing has demonstrated a high level of compatibility and complementarity between BlastX and the Wound Vac therapy of KCI. We would expect a much-improved performance from BlastX in CY20 and NXS generally. We retain ourBUY recommendation.
Canacord TodayNXS-ASX | Dec quarterly; maintain BUY and A$3.04...
-
- There are more pages in this discussion • 401 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.010(5.41%) |
Mkt cap ! $56.97M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 18.5¢ | $16.10K | 83.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4342 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 31280 | 1 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| NXS (ASX) Chart |